Skip to main content
Fig. 1 | Journal of Orthopaedic Surgery and Research

Fig. 1

From: Roxadustat promotes osteoblast differentiation and prevents estrogen deficiency-induced bone loss by stabilizing HIF-1α and activating the Wnt/β-catenin signaling pathway

Fig. 1

Roxadustat promoted osteoblast differentiation and extracellular matrix mineralization. A The viability of osteoblasts treated with roxadustat at different concentrations (0–20 μM) for 1 to 7 days, as determined by CCK-8 assays. B, C ALP staining at day 7. D Alizarin Red S staining at day 14. E Quantification of extracellular matrix mineralization. Data are presented as the mean ± SD of three independent experiments; **P < 0.01, compared with the control group (the 0 μM roxadustat treatment group)

Back to article page

Journal of Orthopaedic Surgery and Research

ISSN: 1749-799X